Dr. Reddy's Makes Headway With Phase III PPAR Compound; Will It Be The First Innovative Indian Product To Reach The Market?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Hope was rekindled for India's Dr. Reddy's Labs to put its own experimental drug in the market after the Hyderabad-headquartered company announced that its lead type 2 diabetes compound balaglitazone succeeded in meeting the primary endpoint in Phase III trials